LONDON–(BUSINESS WIRE)–#RareDiseases–The latest market research report by Technavio
on the global
hepatic encephalopathy (HE) therapeutics market predicts
a CAGR of more than 5% during the period 2018-2022.
The report segments the global hepatic encephalopathy therapeutics
market by product (NADs and antibiotics) and by geography (the Americas,
EMEA, and APAC). It provides a detailed illustration of the major
factors influencing the market, including drivers, opportunities,
trends, and industry-specific challenges.
Here are some key findings of the global hepatic encephalopathy
therapeutics market, according to Technavio healthcare
and life sciences researchers:
- Availability of co-pay assistance programs: a major market driver
- Emergence of novel treatment targets: emerging market trend
- The Americas dominated the global hepatic encephalopathy therapeutics
market with close to 43% share in 2017
- ASKA Pharmaceutical, COSMO PHARMACEUTICALS, Mallinckrodt, and Valeant
Biomet are some of the leading players in this market
This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the
third for FREE: View
all Technavio’s current offers
Availability of co-pay assistance programs: a major market driver
Therapeutics are generally sold at a remarkably higher cost price to
provide better profit margins for the drugs. This is done to encourage
the vendors as they incur high development cost for the drug. Patients
might pay a certain cost, known as co-pay, for the therapeutic and the
insurer covers the remaining cost. In several instances, the burden of
co-pay has been taken over by the vendors. Such co-pay assistance has a
two-pronged impact on the market. It helps in increasing the patient
adherence to approved therapies by reducing the adoption of inexpensive
alternatives. It also increases the sales volume of therapeutics.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report including the market size and forecast, drivers,
challenges, trends, and more.
Emergence of novel treatment targets: emerging market trend
At present, lactulose and rifaximin are the most commonly used
therapeutics to treat HE. Treatments targeting ammonia production and
removal are also emerging in the market. Inflammation is an important
factor that is associated with the progression and development of HE.
Therefore, there are various treatments that target inflammation. Some
of the most recent approaches include the use of probiotics, albumin
administration, and dialysis.
According to a senior analyst at Technavio for research on infectious
and rare diseases, “Probiotics reduce the levels of ammonia
and endotoxin in the blood by introducing a microorganism into the body.
They also reduce inflammation and oxidative stress in hepatocytes. Thus,
they can be used in the treatment of HE. Probiotics also provide
secondary protection against further episodes through the replacement of
urease-producing species with non-urease-producing species. Hence, the
emergence of novel treatment targets will drive the growth of the global
HE therapeutics market during the forecast period.”
Global market opportunities
The Americas dominated the global hepatic
encephalopathy therapeutics market, accounting for a share of
approximately 43% during the forecast period. The EMEA region accounted
for the second largest share in the market, and the APAC region
accounted for the least share in the market. During the forecast period,
the highest incremental growth is expected to originate from the
Big savings with Technavio this February!
Get 20% OFF on all Education
Celebrate winter sports with 23% OFF all reports in our Outdoor
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200